Littérature scientifique sur le sujet « Anti-cytokines vaccination »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Anti-cytokines vaccination ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Anti-cytokines vaccination"
Agrati, Chiara, Concetta Castilletti, Delia Goletti, Silvia Meschi, Alessandra Sacchi, Giulia Matusali, Veronica Bordoni et al. « Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine ». Microorganisms 9, no 6 (16 juin 2021) : 1315. http://dx.doi.org/10.3390/microorganisms9061315.
Texte intégralRamakrishnan, Amritha, Keri Altoff, Andrew Pekosz et Jay Bream. « Immune Response to Seasonal Influenza Vaccination (92.18) ». Journal of Immunology 184, no 1_Supplement (1 avril 2010) : 92.18. http://dx.doi.org/10.4049/jimmunol.184.supp.92.18.
Texte intégralShen, Chih-Lung, Tso-Fu Wang, Chao-Zong Liu et Yi-Feng Wu. « Platelet Activation and Cytokine Release of Interleukin-8 and Interferon-Gamma-Induced Protein 10 after ChAdOx1 nCoV-19 Coronavirus Vaccine Injection ». Vaccines 11, no 2 (16 février 2023) : 456. http://dx.doi.org/10.3390/vaccines11020456.
Texte intégralTrofin, Felicia, Olivia Simona Dorneanu, Daniela Constantinescu, Eduard Vasile Nastase, Cătălina Luncă, Luminița Smaranda Iancu, Ioana-Maria Andrioaie et al. « Cytokines and Chemokines in Breastmilk of SARS-CoV-2 Infected or COVID-19 Vaccinated Mothers ». Vaccines 10, no 12 (24 novembre 2022) : 2001. http://dx.doi.org/10.3390/vaccines10122001.
Texte intégralGazzinelli, R. T., F. T. Hakim, S. Hieny, G. M. Shearer et A. Sher. « Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. » Journal of Immunology 146, no 1 (1 janvier 1991) : 286–92. http://dx.doi.org/10.4049/jimmunol.146.1.286.
Texte intégralWeir, Rosemary E., Gillian F. Black, Hazel M. Dockrell, Sian Floyd, Paul E. M. Fine, Steven D. Chaguluka, Sally Stenson et al. « Mycobacterial Purified Protein Derivatives Stimulate Innate Immunity : Malawians Show Enhanced Tumor Necrosis Factor Alpha, Interleukin-1β (IL-1β), and IL-10 Responses Compared to Those of Adolescents in the United Kingdom ». Infection and Immunity 72, no 3 (mars 2004) : 1807–11. http://dx.doi.org/10.1128/iai.72.3.1807-1811.2004.
Texte intégralKhare, Priyanka, Saleem Javed, Swatantra Jain, Om Singh et Rahul Pal. « Potential roles of human chorionic gonadotropin in tumorigenesis and the development of novel vaccination strategies (P2116) ». Journal of Immunology 190, no 1_Supplement (1 mai 2013) : 132.48. http://dx.doi.org/10.4049/jimmunol.190.supp.132.48.
Texte intégralPonikowska, Irena, Przemysław Adamczyk et Zbigniew Kupis. « Balneotherapy in Stimulating Resistance to Infections – the Little-used Health Resort’s Potential During the COVID-19 Pandemic ». Acta Balneologica 64, no 3 (2021) : 264–68. http://dx.doi.org/10.36740/abal202203111.
Texte intégralBlackwood, Catherine B., Emel Sen-Kilic, Dylan T. Boehm, Jesse M. Hall, Melinda E. Varney, Ting Y. Wong, Shelby D. Bradford et al. « Innate and Adaptive Immune Responses against Bordetella pertussis and Pseudomonas aeruginosa in a Murine Model of Mucosal Vaccination against Respiratory Infection ». Vaccines 8, no 4 (3 novembre 2020) : 647. http://dx.doi.org/10.3390/vaccines8040647.
Texte intégralHammer, Adam, Jonathan Eby, Emily Gilbert, Safia Kahn, Daniel Dilling et I. Le Poole. « Vaccination with GD3 synthase provides tumor protection against melanoma in mice (P4461) ». Journal of Immunology 190, no 1_Supplement (1 mai 2013) : 126.14. http://dx.doi.org/10.4049/jimmunol.190.supp.126.14.
Texte intégralThèses sur le sujet "Anti-cytokines vaccination"
Belmellat-Bouadi, Nadia. « Etude de l’efficacité des stratégies d’immunothérapies actives anti-cytokine et évaluation des conséquences de la vaccination anti-TNF dans des modèles infectieux ». Thesis, Sorbonne Paris Cité, 2016. http://www.theses.fr/2016USPCD028/document.
Texte intégralRheumatoid arthritis (RA) is the most frequent inflammatory rheumatism. This disease is accompanied by hyperplasia of the synovial membrane surrounding the joint. Pannus formation is controlled by pro-inflammatory and pro-angiogenic cytokines. Anti-TNF immunotherapies used in the treatment of RA presents many drawbacks (loss of efficacy, infections), which leaves some place for the development of an anti-TNF immunization strategy. In the first part of my work, we developed an anti-VEGF vaccine to study the links between angiogenesis and inflammation in collagen-induced arthritis (CIA) model. In the second part, we developed a mouse anti-TNF vaccine to assess the consequences of the neutralization of TNF-α by vaccination in infectious models. Inhibition of VEGF with a vaccine consisting of whole VEGF or VEGF peptide coupled to KLH, showed a clinical and histological protection in the CIA model. In the second part of my work, we developed a mouse anti-TNF vaccine (TNF-KLH). This vaccine is as effective as etanercept in CIA, but does not increase the risk of infection in Mycobacterium tuberculosis model. In Listeria monocytogenes model, unlike etanercept, immunization with TNF-KLH does not increase the bacterial burden and mortality. My work contributed to the development of active anti-VEGF vaccine and our results show a partial protection with this strategy. Also, we demonstrate that targeting TNF by active immunotherapy does not alter the immune response in our models of infections
Delavallée, Laure. « Vaccination anti-TNF dans la polyarthrite rhumatoïde ». Paris 13, 2009. http://www.theses.fr/2009PA132031.
Texte intégralRheumatoid Arthritis (RA) is the most frequent inflammatory rheumatism, consequence of chronic articular inflammation followed by articular destruction. Although its precise etiology is still unknown, major role of cytokines imbalance was demonstrated in its pathogenesis. Better comprehension of RA pathophysiological mecanisms induced development of immunotherapies targeting pro-inflammatory cytokines, in particular TNF-α (monoclonal antibodies, soluble receptor). These targeted treatment to TNF have demonstrated their efficacy in RA. However, primary unresponsiveness or secondary escape to these treatments can occur and give rise to new alternative strategies to target this cytokine. The main objective of our research work consisted in demonstrating anti-TNF vaccination (TNF-K) concept in treatment of experimental polyarthritis, in evaluating its degree of efficacy as well as experimental benefit/risk ratio of such a strategy. We show clinical efficiency of TNF-K treatment in polyarthritis experimental model. We show a bell-shaped evolution of neutralizing anti-TNF antibodies during time. We demonstrate that TNF blockade is sufficient to observe the expected effects, but still leave residual production of active cytokine. We bring evidence of an anti-TNF-K cellular response to KLH, but not to TNF, and we showed that only TNF injection do not induce the production of new neutralizing anti-TNF antibody in immunized mice. All these data are consistent with a favorable immunological profile of TNF-K regarding benefit/risk ratio. Besides, we report for the first time evolution of human TNF transgenic mice arthritides on one year follow-up
Conde, García Eva. « Anti -IL-4, -IL-13 and -IgE vaccination for the treatment of allergic diseases ». Thesis, Sorbonne université, 2020. https://accesdistant.sorbonne-universite.fr/login?url=http://theses-intra.upmc.fr/modules/resources/download/theses/2020SORUS011.pdf.
Texte intégralAllergies represent major public health problems of increasing prevalence and for which there is still no efficient long-term therapy. IL-4 and IL-13, and IgE play key roles in allergic reactions, and therefore represent good therapeutic targets. These targets have been clinically validated with approved monoclonal antibodies (mAb). However, use of mAb is limited by high cost and the need to perform repeated injections. Therefore, there is a clear need to improve current strategies in order to reach long term effects. The objective of this thesis was to develop anti-IL-4, anti-IL-13 and anti-IgE vaccines called kinoids, and provide a proof-of-concept of their safety and efficacy. We developed conjugate vaccines against IL-4 and IL-13, and demonstrated their prophylactic and therapeutic efficacy in reducing IgE levels, airway hyperresponsiveness, eosinophilia and mucus production in a house dust mite-induced mouse model of asthma without any detectable adverse effect. The human version of the IL-4/IL-13 kinoid was also efficient at neutralizing human IL-4 and IL-13, and reducing IgE levels in mice humanized for IL-4, IL-13 and their common receptor subunit IL-4Ra. In addition, we also developed a conjugate vaccine against human IgE. We showed that this anti-IgE vaccine induces long-term production of anti-human IgE neutralizing antibodies in a novel mouse strain we characterized and which is humanized for IgE and its high-affinity receptor FceRI. Anti-human IgE vaccination reduced hIgE, and fully protected against IgE-mediated anaphylaxis. Altogether, our results showed that vaccination against IL-4, IL-13 and IgE could be a valuable strategy to target allergic disorders